Pulse Biosciences rises on FDA approval to test its heart device

Pulse Biosciences

08/09/2025 12:37

** Shares of biotech co Pulse Biosciences PLSE.O rise 6.4% to $16.08 premarket

** Co says U.S. FDA has granted approval for co to test its heart device for the treatment of atrial fibrillation or irregular heart rhythm

** The study plans to enroll up to 136 patients and is designed to test the effectiveness of the device called Nanosecond Pulsed Field Ablation

     ** The device is designed to deliver continuous ablations during cardiac surgeries

** Up to last close, stock down 13.2% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))